Drug Patents owned by Gilead Sciences
1. List of Atripla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9744181 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US8716264 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US8592397 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US9457036 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US9545414 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(3 years from now) | |
| US9018192 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(3 years from now) | |
| US8598185 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Apr, 2029
(6 years from now) | |
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in adults
Dosage: TABLET;ORAL
How can I launch a generic of ATRIPLA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic